PCMC
PMCB icon

Planning Capital Management Corporation’s PharmaCyte Biotech PMCB Stock Holding History

Planning Capital Management Corporation’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$191 Hold
100
– – ﹤0.01% 703
2024
Q2 		$196 Buy
+100
New +$215 ﹤0.01% 649

Other funds holding PMCB

KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Planning Capital Management Corporation's PMCB Position: Q3 2024 in Review

Planning Capital Management Corporation held its PharmaCyte Biotech (PMCB) position steady in Q3 2024 at 100 shares worth $191. The position accounts for ﹤0.01% of the portfolio, ranked #703.

Planning Capital Management Corporation first reported a position in PMCB in Q2 2024 and has held it in 2 quarters since. The position peaked at $196 in Q2 2024. 26 funds tracked by Wall St. Rank hold PMCB as of Q3 2024.

  • Planning Capital Management Corporation held 100 shares of PharmaCyte Biotech worth $191 as of Q3 2024.
  • Planning Capital Management Corporation left its PharmaCyte Biotech share count unchanged in Q3 2024.
  • PharmaCyte Biotech made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #703 holding.
  • Planning Capital Management Corporation first reported a position in PharmaCyte Biotech in Q2 2024 and has held it in 2 quarters since.
  • Planning Capital Management Corporation's PharmaCyte Biotech position peaked at $196 in Q2 2024.
  • 26 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.